Bristol Myers Squibb (NYSE: BMY) showcased its robust cardiovascular franchise at the European Society of Cardiology (ESC) Congress in London.
CAMZYOS
• Long-term data (up to 3.5 years) demonstrated the sustained efficacy and safety of CAMZYOS (mavacamten) in treating obstructive hypertrophic cardiomyopathy (oHCM).
ELIQUIS (Apixaban)
• Data from the BMS-Pfizer Alliance supported the use of ELIQUIS for anticoagulation and thrombosis management.
Milvexian
• Data from the BMS-Johnson & Johnson Collaboration contributed to the understanding of milvexian for the treatment of oHCM.
Key Findings
• CAMZYOS is well-aligned with ESC guidelines for treating oHCM in Germany.
• Non-obstructive hypertrophic cardiomyopathy remains understudied, highlighting the need for further research.
• Serial monitoring of left and right ventricular strain can provide insights into the effects of mavacamten treatment for oHCM.
Bristol Myers Squibb’s Commitment
Roland Chen, Head of Immunology, Cardiovascular & Neuroscience Development, emphasized the company’s dedication to improving the lives of patients with cardiovascular diseases. Bristol Myers Squibb aims to advance the development of medicines for anticoagulation, thrombosis management, and the treatment of oHCM.
Abstracts and further details on Bristol Myers Squibb’s cardiovascular research can be accessed online and on BMS.com.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
